Skip to content
Back to outputs

Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil

Research output: Contribution to journalArticle

Standard

Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil. / Gutiérrez, Héctor Carreño; Vacca, Irene; Schoenmacker, Gido; Cleal, Madeleine; Tochwin, Anna; O'Connor, Bethan; Young, Andrew M.J.; Vasquez, Alejandro Arias; Winter, Matthew J.; Parker, Matthew O.; Norton, William H. J.

In: European Neuropsychopharmacology, 01.11.2019.

Research output: Contribution to journalArticle

Harvard

Gutiérrez, HC, Vacca, I, Schoenmacker, G, Cleal, M, Tochwin, A, O'Connor, B, Young, AMJ, Vasquez, AA, Winter, MJ, Parker, MO & Norton, WHJ 2019, 'Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil', European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2019.10.005

APA

Gutiérrez, H. C., Vacca, I., Schoenmacker, G., Cleal, M., Tochwin, A., O'Connor, B., ... Norton, W. H. J. (2019). Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2019.10.005

Vancouver

Gutiérrez HC, Vacca I, Schoenmacker G, Cleal M, Tochwin A, O'Connor B et al. Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil. European Neuropsychopharmacology. 2019 Nov 1. https://doi.org/10.1016/j.euroneuro.2019.10.005

Author

Gutiérrez, Héctor Carreño ; Vacca, Irene ; Schoenmacker, Gido ; Cleal, Madeleine ; Tochwin, Anna ; O'Connor, Bethan ; Young, Andrew M.J. ; Vasquez, Alejandro Arias ; Winter, Matthew J. ; Parker, Matthew O. ; Norton, William H. J. / Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil. In: European Neuropsychopharmacology. 2019.

Bibtex

@article{29ebfd94633f4c02918ba95a8dd78d81,
title = "Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil",
abstract = "Although aggression is a common symptom of psychiatric disorders the drugs available to treat it are non-specific and can have unwanted side effects. In this study we have used a behavioural platform in a phenotypic screen to identify drugs that can reduce zebrafish aggression without affecting locomotion. In a three tier screen of ninety-four drugs we discovered that caffeine and sildenafil can selectively reduce aggression. Caffeine also decreased attention and increased impulsivity in the 5-choice serial reaction time task whereas sildenafil showed the opposite effect. Imaging studies revealed that both caffeine and sildenafil are active in the zebrafish brain, with prominent activation of the thalamus and cerebellum evident. They also interact with 5-HT neurotransmitter signalling. In summary, we have demonstrated that juvenile zebrafish are a suitable model to screen for novel drugs to reduce aggression, with the potential to uncover the neural circuits and signalling pathways that mediate such behavioural effects.",
author = "Guti{\'e}rrez, {H{\'e}ctor Carre{\~n}o} and Irene Vacca and Gido Schoenmacker and Madeleine Cleal and Anna Tochwin and Bethan O'Connor and Young, {Andrew M.J.} and Vasquez, {Alejandro Arias} and Winter, {Matthew J.} and Parker, {Matthew O.} and Norton, {William H. J.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.euroneuro.2019.10.005",
language = "English",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil

AU - Gutiérrez, Héctor Carreño

AU - Vacca, Irene

AU - Schoenmacker, Gido

AU - Cleal, Madeleine

AU - Tochwin, Anna

AU - O'Connor, Bethan

AU - Young, Andrew M.J.

AU - Vasquez, Alejandro Arias

AU - Winter, Matthew J.

AU - Parker, Matthew O.

AU - Norton, William H. J.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Although aggression is a common symptom of psychiatric disorders the drugs available to treat it are non-specific and can have unwanted side effects. In this study we have used a behavioural platform in a phenotypic screen to identify drugs that can reduce zebrafish aggression without affecting locomotion. In a three tier screen of ninety-four drugs we discovered that caffeine and sildenafil can selectively reduce aggression. Caffeine also decreased attention and increased impulsivity in the 5-choice serial reaction time task whereas sildenafil showed the opposite effect. Imaging studies revealed that both caffeine and sildenafil are active in the zebrafish brain, with prominent activation of the thalamus and cerebellum evident. They also interact with 5-HT neurotransmitter signalling. In summary, we have demonstrated that juvenile zebrafish are a suitable model to screen for novel drugs to reduce aggression, with the potential to uncover the neural circuits and signalling pathways that mediate such behavioural effects.

AB - Although aggression is a common symptom of psychiatric disorders the drugs available to treat it are non-specific and can have unwanted side effects. In this study we have used a behavioural platform in a phenotypic screen to identify drugs that can reduce zebrafish aggression without affecting locomotion. In a three tier screen of ninety-four drugs we discovered that caffeine and sildenafil can selectively reduce aggression. Caffeine also decreased attention and increased impulsivity in the 5-choice serial reaction time task whereas sildenafil showed the opposite effect. Imaging studies revealed that both caffeine and sildenafil are active in the zebrafish brain, with prominent activation of the thalamus and cerebellum evident. They also interact with 5-HT neurotransmitter signalling. In summary, we have demonstrated that juvenile zebrafish are a suitable model to screen for novel drugs to reduce aggression, with the potential to uncover the neural circuits and signalling pathways that mediate such behavioural effects.

U2 - 10.1016/j.euroneuro.2019.10.005

DO - 10.1016/j.euroneuro.2019.10.005

M3 - Article

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

ER -

ID: 16091056